0916 ET - Kura Oncology's agreement to develop and commercialize its cancer drug wasn't what the doctor ordered, as far as investors are concerned. The biotech company announced a deal with Kyowa Kirin related to ziftomenib, its potential leukemia-treating oral menin inhibitor therapy. Stifel analysts say in a research note that despite it being arguably a good deal for the economics of the drug, investors were looking for a large pharma transaction and will be disappointed. The commercialization deal likely closes off a possible acquisition by a larger company also developing blood-cancer treatments, they say. Investors now have to figure out how to value the company's large cash balance, given a limited valuation for the company's lead drug. Kura nosedives 26% premarket. (ben.glickman@wsj.com; @benglickman)
(END) Dow Jones Newswires
November 21, 2024 09:16 ET (14:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。